Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

660 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions - proceedings from the CEC Summit 2018.
Sharma A, Mahaffey KW, Gibson CM, Hicks KA, Alexander KP, Ali M, Chaitman BR, Held C, Hlatky M, Jones WS, Mehran R, Menon V, Rockhold FW, Seltzer J, Spitzer E, Wilson M, Lopes RD. Sharma A, et al. Among authors: mahaffey kw. Am Heart J. 2022 Apr;246:93-104. doi: 10.1016/j.ahj.2021.12.012. Epub 2021 Dec 31. Am Heart J. 2022. PMID: 34973948 Free article.
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial.
Mahaffey KW, Roe MT, Dyke CK, Newby LK, Kleiman NS, Connolly P, Berdan LG, Sparapani R, Lee KL, Armstrong PW, Topol EJ, Califf RM, Harrington RA. Mahaffey KW, et al. Am Heart J. 2002 Feb;143(2):242-8. doi: 10.1067/mhj.2002.120145. Am Heart J. 2002. PMID: 11835026
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.
Petersen JL, Mahaffey KW, Becker RC, Goodman SG, Kleiman NS, Marian AJ, Stone GW, Lansky AJ, Lincoff AM, Hazen SL, Nessel CC, Toro-Figueroa L, Tate L, Reist CJ, Cohen M, Califf RM, Ferguson JJ; SYNERGY Library. Petersen JL, et al. Among authors: mahaffey kw. Am Heart J. 2004 Aug;148(2):269-76. doi: 10.1016/j.ahj.2004.03.022. Am Heart J. 2004. PMID: 15308996 Clinical Trial.
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials.
Galla JM, Mahaffey KW, Sapp SK, Alexander JH, Roe MT, Ohman EM, Granger CB, Armstrong PW, Harrington RA, White HD, Simoons ML, Newby LK, Califf RM, Topol EJ. Galla JM, et al. Among authors: mahaffey kw. Am Heart J. 2006 Jan;151(1):16-24. doi: 10.1016/j.ahj.2005.01.045. Am Heart J. 2006. PMID: 16368286
Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis.
Murphy SA, Gibson CM, Morrow DA, Van de Werf F, Menown IB, Goodman SG, Mahaffey KW, Cohen M, McCabe CH, Antman EM, Braunwald E. Murphy SA, et al. Among authors: mahaffey kw. Eur Heart J. 2007 Sep;28(17):2077-86. doi: 10.1093/eurheartj/ehm224. Epub 2007 Jun 28. Eur Heart J. 2007. PMID: 17600038 Review.
Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV).
Yau JM, Alexander JH, Hafley G, Mahaffey KW, Mack MJ, Kouchoukos N, Goyal A, Peterson ED, Gibson CM, Califf RM, Harrington RA, Ferguson TB; PREVENT IV Investigators. Yau JM, et al. Among authors: mahaffey kw. Am J Cardiol. 2008 Sep 1;102(5):546-51. doi: 10.1016/j.amjcard.2008.04.069. Epub 2008 Jul 2. Am J Cardiol. 2008. PMID: 18721510 Clinical Trial.
660 results